Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00061672 · ClinicalTrials.gov registry record · Phase 2
Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects With Refractory Lymphoma
A Phase 2 study of Lymphoma, Non-Hodgkin and Hodgkin's Lymphoma, sponsored by Abbott.
- Completed
- Registry status
- Phase 2
- Development phase
- 67
- Enrollment target
- 14
- Study locations
NCT00061672: Completed Phase 2 study of Lymphoma, Non-Hodgkin and Hodgkin's Lymphoma, sponsored by Abbott.
NCT00061672 is a Phase 2 study of Lymphoma, Non-Hodgkin and Hodgkin's Lymphoma that has completed, run by Abbott. The registered enrollment target is 67 participants, below the 388-participant average among 58 other Lymphoma, Non-Hodgkin trials with a reported enrollment target (83% lower). The trial reports 14 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00061672, a Phase 2 study of Lymphoma, Non-Hodgkin and Hodgkin's Lymphoma, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 67 participants
- Enrollment target
- 14
- Study locations
Study Summary
The primary objective of this study is to assess the safety and effectiveness of ABT-510 in subjects with refractory lymphoma.
Conditions Studied
Interventions
- DRUG ABT-510 - Thrombospondin-1 Mimetic
Study Locations (14)
Florida
- The Center for Hematology-Oncology - Boca Raton
- Oncology-Hematology Group of South Florida - Miami
- Cancer Centers of Florida, P.A. - Orlando
Arizona
- Hematology Oncology Associates - Phoenix
- Arizona Clinical Research Center - Tucson
Missouri
- Kansas City Oncology and Hematology Group - Kansas City
- Arch Medical Services, INC. - St Louis
Texas
- MD Anderson Cancer Center - Houston
- Hematology Oncology Associates - San Antonio
California
- USC - Norris Cancer Center - Los Angeles
New York
- Albany Regional Cancer Center - Albany
North Carolina
- Raleigh Hematology Oncology Clinic - Cary
Tennessee
- The West Cancer Clinic - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2003-04 |
| Phase | Phase 2 |
What the finished NCT00061672 record still lists
NCT00061672 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 67 participants, a relatively small participant target, below the 388-participant average among 58 other Lymphoma, Non-Hodgkin trials with a reported enrollment target (83% lower).
The record links to 2 conditions, with Lymphoma, Non-Hodgkin appearing as the primary indexed condition, and to 1 intervention - of which ABT-510 - Thrombospondin-1 Mimetic is the first listed.
NCT00061672 lists 14 locations in 9 states (Florida, Arizona, Missouri).
Frequently Asked Questions
What is clinical trial NCT00061672 about?
NCT00061672 is a clinical study titled "Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects With Refractory Lymphoma". The primary objective of this study is to assess the safety and effectiveness of ABT-510 in subjects with refractory lymphoma.
What is the current status of trial NCT00061672?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 67 participants. The study started on 2003-04.
What conditions does trial NCT00061672 study?
This clinical trial studies the following conditions: Lymphoma, Non-Hodgkin, Hodgkin's Lymphoma.
What interventions are being tested in trial NCT00061672?
The interventions under investigation include: ABT-510 - Thrombospondin-1 Mimetic (DRUG).
Who is sponsoring clinical trial NCT00061672?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00061672 being conducted?
This trial has 14 study locations across Arizona, California, Florida, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma, Non-Hodgkin
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00061672's enrollment target sits among peer trials
67 30th of 58 higher than 29 of 58 other Lymphoma, Non-Hodgkin trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphoma, Non-Hodgkin trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Epcoritamab-CAR T Cells for Large B-cell Lymphomas
RECRUITING · Phase 2
-
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
RECRUITING · Phase 2
-
Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases
RECRUITING · Phase 2
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03213002 · 67 participants · Phase 1
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
- NCT04115163 · 67 participants · Phase 2
Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
- NCT04315324 · 67 participants · Phase 1
Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)
- NCT04532424 · 67 participants · NA
Transcranial Magnetic Stimulation for Restricted and Repetitive Behavior in ASD
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia